Norwegian Association for Psychedelic Science is a non-profit organization run by academics and researchers within psychedelic science in Norway. Our mission is to enhance scientific enquiry into psychedelic substances and their clinical potential.
What do we do?
NPS mission is to build a network of scientists, academics and students, as well as organize activities that enhance the development of scientific research on psychedelics.
Dissemination of knowledge
We organize lectures about psychedelics science that are open to the public, as well as creating a resource bank with scientific literature.
We help researchers and academics come in contact with other researchers interested in the field, in order to promote cooperation within and across disciplines.
Assist student members
We assist students who are interested in writing about psychedelic science or preparing for a future career within the field.
Nordic Psychedelic Science Conference
Part of our mission is to organize the first psychedelic science conference in Norway in 2021
Fyll ut skjemaet under for å bli medlem av Norsk Forening for Psykedelisk Vitenskap
NPS is run by academics and researchers involved in psychedelic science in Norway. We have different academic and professional backgrounds and are interested in a wide range of topics.
Chairman, social anthropologist
Anna Høifødt is a social anthropologist who has studied the use of psychedelics among different groups in Norway. For her thesis "The Value of Experience: Psychedelics, phenomenology and contemporary perspectives on drug use", she was given the "Våg og Vite" award in 2018.
Dr. Lowan Stewart
Second chairman, MD, specialist in emergency medicine
Lowan Stewart has over 20 years of experience with clinical use of ketamine. He is a specialist in emergency medicine and a fellow at the American Academy of Emergency Medicine and American College of Emergency Medicine, and a member of the American Society of Ketamine Physicians. He is the medical advisor at PsykForsk, working on international clinical trials on ketamine, esketamine, MDMA and psilocybin for the treatment of mental health disorders.
Clinical psychologist, specialist
Ivar W. Goksøyr is a psychologist specialized within Intensive short-term dynamic psychotherapy (ISTDP). Goksøyr is affiliated with the unit "Psykforsk - Innovative Treatment Research", at the Hospital in Østfold. He works here to prepare participation in international treatment studies with psychedelic drugs. He has received training in MDMA-assisted psychotherapy by the Multidisciplinary Association for Psychedelic Studies (MAPS) and treatment with Psilocybin.
Dr. Attila Szabo
Attila Szabo is a Postdoctoral Fellow at the Norwegian Centre for Mental Disorders Research (NORMENT), University of Oslo. His current research focuses on serotonin and sigma receptors, their modulatory role in immune responses and cellular functions. In this context, he is specifically interested in the regulatory potential of dimethyltryptamine (DMT) and its analogues on human immune cell, neuron, and glia functions under various physiological conditions.
Senior consultant psychiatrist
Tor-Morten Kvam is affiliated with the unit "Psykforsk - Innovative Treatment Research", at the Hospital in Østfold and is involved with the preparation of clinical studies with psilocybin and MDMA. He has published a review article in the Journal of the Norwegian Medical Association about the use of psychedelics in clinical treatment.
Kristoffer Andersen is a clinical psychologist who has experience working with personality disorders, substance abuse and trauma populations. In 2019 he completed a MAPS training program as adherence rater and provides evaluation of therapist's in MDMA-assisted psychotherapy trials. Currently he specializes in dynamic psychotherapy and works full time as clinical psychologist at an out-patient unit in Norway.
Malin Vedøy Uthaug
Malin Vedøy Uthaug has a background in psychology and is currently a Research Assistant (RA) at Imperial College London. Her doctoral research centers around the investigation of the effects of Ayahuasca ingested in a naturalistic setting on affect and cognition, in addition to pioneering work on the effects of 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT) in humans.
Andreas Wahl Blomkvist
MD, general practitioner
Andreas Wahl Blomkvist is a doctor with general medical specialization who is also a writer. Blomkvist has been an active voice in the public debate concerning the effects of drug policies and has written several academic articles. He is currently writing a book about illegal substances and their role in medicine.
Want to become a member of NPS?
- Your membership supports our general work towards supporting psychedelic research in Norway. - Your membership fee is a contribution that goes towards running the organization as well as activities. Everyone who works for NPS are volunteers. - Become a part of our network of scientists, academics and students within psychedelic science in Norway. - Receive information about journal clubs, workshops and lectures.
Become a member
Would you like to give NPS a contribution?
All donations goes directly towards our work with promoting psychedelic science.
VIPPS code 556624 or search for Norsk Psykedelisk Vitenskap